Q2 2021 Results - Reimagining Medicine
Participants
Financial review
Conclusion
Appendix
Company overview
Pharmaceuticals
Oncology
Financial performance
Innovation: Pipeline overview
Novartis submission schedule
Supplementary indications for existing brands
References
Innovation: Clinical trials
2021
alpelisib
LCM
BYL719
PROS
Beovu
LCM
brolucizumab, RTH258
DME
canakinumab¹
LCM
Cosentyx
2022
secukinumab, AIN457
PSA IVIV
Cosentyx
secukinumab, AIN457
AS H2H
Cosentyx
2023
LCM canakinumab
ACZ885
Adjuvant NSCLC
2024
LCM
Adakveo
SEG101
LCM Aimovig
Sickle cell anaemia with crisis ped
erenumab, AMG334
Pediatric Migraine
≥2025
LCM Cosentyx
LCM Leqvio
LCM
secukinumab, AIN457
Lupus Nephritis
KJX839
CVRR-LDLC
LCM Cosentyx
LCM
Beovu
LCM aflibercept
BioS
secukinumab, AIN457
AS IVIV
brolucizumab, RTH258
RVO4
SOK583
Neovascular age-related macular degeneration
Cosentyx
secukinumab, AIN457
Lichen Planus
LCM
Mayzent
LCM
siponimod, BAF312
Pediatric MS
LCM Denosumab
BioS
Coartem
LCM
Beovu
LCM Jakavi
LCM
Piqray
LCM
ACZ885
NSCLC 1L
secukinumab, AIN457
Hidradenitis suppurativa
GP2411
artemether + lumefantrine, COA566
brolucizumab, RTH258
ruxolitinib, INC424
alpelisib, BYL719
anti RANKL mAb
Malaria uncompl., formula for <5kg
Diabetic retinopathy
Myelofibrosis (combination)
HER2+ adv BC
Cosentyx
LCM
Entresto EU²
LCM Kisqali
LCM
Cosentyx
LCM
Kymriah
LCM
OAV101
LCM
secukinumab, AIN457
sacubitril/valsartan, LCZ696
Juvenile idiopathic arthritis
Pediatric CHF
ribociclib, LEE011
HR+/HER2- BC (adj)
secukinumab, AIN457
tisagenlecleucel, CTL019
GCA
1L high risk ALL, pediatrics & young adults
AVXS-101
SMA IT
Jakavi
LCM
Tafinlar + Mekinist
LCM
Lutathera
LCM
Jakavi
LCM
ruxolitinib, INC424
Chronic GVHD
dabrafenib + trametinib, DRB436
HGG/LGG Pediatrics
177Lu-oxodotreotide³
GEP-NET 1L G3
ruxolitinib, INC424
Pediatrics Acute GVHD
Jakavi
LCM
Xolair
LCM Piqray
LCM
Jakavi
LCM
ruxolitinib, INC424
omalizumab, IGE025
alpelisib, BYL719
ruxolitinib, INC424
Acute GVHD
Auto-injector
TNBC
Pediatrics Chronic GVHD
Kymriah
LCM
Piqray
LCM
Leqvio
LCM
tisagenlecleucel, CTL019
alpelisib, BYL719
KJX839
aNHL 2L
Ovarian cancer
Ped Hyperlipidemia
Kymriah
LCM
Promacta
LCM
Tafinlar+ Mekinist
LCM
tisagenlecleucel, CTL019
eltrombopag, ETB115
r/r Follicular lymphoma
Radiation sickness syndrome
dabrafenib + trametinib, DRB436
Thyroid cancer
Xolair
LCM
omalizumab, IGE025
Food allergy
1. Depending on timing of final read-out submission may move to early 2022. 2. Approved in US.
3. 177Lu-dotatate in US. 4. Under evaluation.
54 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation